Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD

May Validate Small Molecule Platform

Executive Summary

The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.

You may also be interested in...



UK Vaccine Taskforce’s Clive Dix: IP Is A Distraction, We Need To Vaccinate The World As Fast As Possible

Clive Dix, who recently stepped down as chair of the UK Vaccine Taskforce, shares his views on its success with Scrip, why AstraZeneca has been unfairly criticized, how the UK should now share its doses with other countries, and the exciting future of vaccine technology.

UK Vaccine Taskforce’s Clive Dix: IP Is A Distraction, We Need To Vaccinate The World As Fast As Possible

Clive Dix, who recently stepped down as chair of the UK Vaccine Taskforce, shares with Pink Sheet his views on its success, why AstraZeneca has been unfairly criticized, how the UK should now share its doses with other countries, and the exciting future of vaccine technology.

Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor

The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel